Skip to main content

Joan Genescà Ferrer

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Joan Genescà Ferrer

Institutions of which they are part

Head of group
Liver Diseases
Vall Hebron Institut de Recerca
Hepatologia
General Hospital

Internal medicine doctor expert in hepatology. Special dedication to advanced liver disease, liver cirrhosis and portal hypertension. Interest in non-invasive methods for the diagnosis and control of liver disease, especially liver elastography. Both clinical and experimental research in animal models of liver disease, including therapeutic studies with nanomedicine.

Chief Liver Unit.
Clinical director of Digestive Diseases.
Professor of Medicine of the UAB.

Projects

Grup de recerca en Malalties Hepàtiques

IP: Joan Genescà Ferrer
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 61192
Reference: 2017SGR0374
Duration: 01/01/2017 - 30/09/2021

Sol·licitud Juan Rodés.

IP: Joan Genescà Ferrer
Collaborators: Macarena Simon-Talero Horga
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR17/00029
Duration: 01/01/2018 - 24/07/2022

Spanish Clinical Research Network (SCReN)

IP: Inmaculada Fuentes Camps
Collaborators: Antonio Moreno Galdó, Tamara Del Rio Higueras, Ariadna Martín Balcells, Olga Sánchez- Maroto Carrizo, Angelica Valderrama Rodríguez, Joan Genescà Ferrer
Funding agency: Instituto de Salud Carlos III
Funding: 319550
Reference: PT17/0017/0030
Duration: 01/01/2018 - 31/12/2020

LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS

IP: Victor Manuel Vargas Blasco
Collaborators: Ester Palacio Gutierrez, Mª Eulàlia Molinas Guilera, Olga Sánchez- Maroto Carrizo, Amaia Latasa Arrazubi, Joan Genescà Ferrer, Cesar Jimenez Hernandez
Funding agency: EUROPEAN COMMISSION
Funding: 409557
Reference: LIVERHOPE_H2020RTD2016
Duration: 01/01/2017 - 28/02/2023

Related news

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

The research team used nanotechnology to deliver the drug directly to liver cells, which eliminated side effects without reducing effectiveness.

Related professionals

Mireia Andres Villarreal

Mireia Andres Villarreal

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Buxo Masip

Xavier Buxo Masip

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more
Laura Mónica Perez  Bazan

Laura Mónica Perez Bazan

Main researcher
Research on Aging, Frailty and Transitions in Barcelona
Read more
Estefania De la Torre Villaescusa

Estefania De la Torre Villaescusa

Head of unit
Teaching Promotion
Teaching Area
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.